Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management

2023-02-27

上市批准快速通道

ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market size is estimated to be $1.8 billion in 2022.2 There is strong evidence for the use of NSAIDs as a first-line treatment for migraine. Celecoxib is in the same class of agents, is fast acting, and has the potential to have the lowest GI side effects of all NSAIDs.3 Strong re-launch commercialization efforts including multiple manuscripts, five posters at American Headache Society (AHS), and more than six thousand interactions with potential customers have laid the groundwork for what Scilex believes will be the successful re-introduction of ELYXYBTM The New Drug Application (NDA) for ELYXYBTM has been transferred to Scilex. Scilex is planning to launch the product in the second quarter of 2023 through its wholly owned subsidiary, Scilex Pharmaceuticals Inc. Scilex is well-positioned to market and distribute ELYXYBTM which is highly complementary to Scilex’s existing commercial offerings. Scilex is negotiating a distribution agreement with a major third-party logistic provider for warehousing and distribution of ELYXYBTM. Scilex has a very experienced commercial and managed care team that has successfully launched and grown market access for ZTlido (lidocaine topical system) for over 200 million covered lives in the U.S. The combined commercial pain portfolio of ZTlido, Gloperba and ELYXYBTM offers end-to-end non-opioid solutions along the pain pathway.

Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc., (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S. Starting today, ELYXYBTM is available in pharmacies to customers and supplied through their normal wholesaler and distributor channels. ELYXYBTM was approved by the U.S. Food and Drug Administration (FDA) on May 6, 2020, for the treatment of acute migraine with or without aura in adults. Strong re-launch commercialization efforts including multiple manuscripts, five posters at American Headache Society (AHS), and more than six thousand interactions with potential customers have laid the groundwork for what Scilex believes will be the successful re-introduction of ELYXYBTM into the outpatient marketplace. “This is an important day for Scilex as the launch of ELYXYB expands our pain management industry leadership and marks a major milestone in our strategy to build a robust offering of novel, non-opioid treatments to improve patient care along the acute and chronic pain pathway,” said Jaisim Shah, Chief Executive Officer and President of Scilex. “ELYXYB is a highly complementary commercial asset that allows us to provide physicians with another tool in their pain management armamentarium to tackle migraines earlier in the patient journey as we continue to redefine the role of opioids as a last resort rescue medication. Importantly, ELYXYB will diversify our revenue stream, enhance our topline, and we believe it will provide meaningful synergies that we expect to drive substantial near- and long-term accretion to our cash flows and earnings.” The Scilex sales force, consists of approximately 65 pain specialists who cover more than 80 percent of the physicians Scilex is targeting for ELYXYBTM. Since we acquired ELYXYBTM, our team has been executing a training and market access strategy, working closely with key customers to initiate the review process to obtain access for ELYXYBTM. “We intend to build off the FDA-approved acute migraine indication through a targeted clinical and regulatory expansion plan encompasses clinical development, partnerships with key clinical leaders and robust publication and medical education plans,” said Dmitri Lissin M.D., Chief Medical Officer of Scilex Holding Company.

About Scilex Holding Company Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R Program for SEMDEXATM, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex has applied for breakthrough therapy designation and expects to seek priority review for SEMDEXATM for the treatment of sciatica. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain. Scilex launched its first commercial product in October 2018, in-licensed a commercial product in June 2022, and is developing its late-stage pipeline, which includes a pivotal Phase 3 candidate and one Phase 2 and one Phase 1 candidate. Its commercial product, ZTlido® (lidocaine topical system) 1.8%, or ZTlido®, is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. Scilex in-licensed the exclusive right to commercialize Gloperba® (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. Scilex is planning to commercialize Gloperba® in 2023 and is well-positioned to market and distribute the product. Scilex’s three product candidates are SP-102 (injectable dexamethasone sodium phosphate viscous gel product containing 10 mg dexamethasone), or SEMDEXA™, a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, with FDA Fast Track status; SP-103 (lidocaine topical system) 5.4%, a Phase 2, triple-strength formulation of ZTlido®, for the treatment of low back pain, with FDA Fast Track status; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia that has completed multiple Phase 1 trial programs and expected to initiate Phase 2 trials this year. For further information regarding the SP-102 Phase 3 efficacy trial, see NCT identifier NCT03372161 – Corticosteroid Lumbar Epidural Analgesia for Radiculopathy – Full Text View – ClinicalTrials.gov. Scilex Holding Company is headquartered in Palo Alto, California. For further information please visit . Reference 1) Source: Celecoxib Oral Solution Approved for Acute Migraine March 2020. 2) Source: Evaluate Pharma data February 16, 2023 3) Source: Acute Migraine Headache: Treatment Strategies. SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned. ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba® is an exclusive, transferable license to use the registered trademark by Scilex Holding Company. ELYXYBTM is an exclusive, transferable license to use the trademark by Scilex Holding Company. All other trademarks are the property of their respective owners. © 2023 Scilex Holding Company All Rights Reserved.

内容来源于网络，如有侵权，请联系删除。

机构

Scilex Holding Co.